From the bi-partisan Research to Accelerate Cures and Equity (RACE) for Children Act implementing an FDA mandate that all new cancer therapies for adults must also be studied in children, to the “Iron Man” of baseball Cal Ripken Jr. announcing he’s cancer free after a February diagnosis, here’s what’s happening in the cancer landscape this week.
Specific measures of a tumor’s texture and intensity as they appear on CT images can help determine how much treatment patients with early stage lung cancer need, a study found.
The Food and Drug Administration (FDA) has approved the expansion of Kyprolis (carfilzomib) in combination to with Darzalex (daratumumab) plus dexamethasone in once- and twice-weekly dosing regimens for the treatment of patients with relapsed or refractory multiple myeloma who have received a maximum of three prior lines of therapy.
Circulating tumor DNA and circulating tumor cells are usual markers for minimal residual disease in patients with triple negative breast cancer, but new research shows they are also valuable indicators of disease recurrence.
In addition to not delaying disease worsening, the immunotherapy Tecentriq was associated with a negative survival trend, but data on the length of life were immature at the time of analysis and further analysis is planned.
“With data showing a two-fold increase in disease-free survival with the vaccine alone and in combination with checkpoint inhibitors, we hope to one day change the narrative for people with melanoma — turning this disease into a chronic condition that can be treated and managed over time,” said Dr. Mark B. Faries.
“This study has highlighted the potential benefit of supportive resources to help women with (metastatic breast cancer) guard against potentially severe cancer-related financial losses for themselves and others within their households,” the authors wrote.
If approved by the FDA, Imfinzi could be administered every four weeks at a fixed dose in patients with stage 3 NSCLC after they received chemoradiation, as well as in patients with previously treated bladder cancer.
While 75% of patients with gynecological cancers and COVID-19 will recover, new data from New York City shows specific risks for patients with cancer infected with COVID-19.
The Food and Drug Administration granted a priority review to the new drug application for trilaciclib for patients with small cell lung cancer.
New research has found that the risk for invasive prostate cancer increases significantly when patients have a family history of PBSIN along with invasive prostate cancer.
From the recent Beirut explosion compromising pediatric oncology hospitals, to researchers looking at how intestinal bacteria can supercharge targeted immunotherapies, here’s what’s happening in the cancer landscape this week.
In patients with diffuse large B-cell lymphoma, low muscle mass (LMM) and low muscle density (LMD) could play a role when deciding what kind of treatment option to pursue, and could also impact a patient’s odds of survival, according to a recent study.
For newly diagnosed patients with ovarian cancer, a recent study shows how too much chemotherapy can lead to less favorable results.
“Unlike other CAR T-cell therapies, clinical success was not associated with significant complications from therapy,” said Dr. Jonathan Serody. “This means this treatment should be available to patients in a clinic setting and would not require patients to be hospitalized, which is critical in our current environment.”
“These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments,” said Dr. John Tsai.
A roundup of the latest news and updates for patients with mantle cell lymphoma from CURE®.
“This study comes from a very honest place. Because I want all patients out there with lung cancer to feel empowered to ask their doctor because they don't have to suffer in silence,” said Dr. Narjust Duma.
On social media, CURE® recently asked its readers to share how they cope with anxiety leading up to their next scans. Here, we share some of their responses.
My care team and I are focused on keeping me alive. And learning to lead them, especially with me having limited medical knowledge, has been essential to helping them keep me alive.
The liquid biopsy test was also approved as a companion diagnostic test to uncover EGFR mutations in patients with NSCLC who could benefit from treatment with Tagrisso.
After a traumatic event, such as breast cancer, it's important for a person to self-monitor. Feelings of anxiety or depression can be debilitating, but there's no reason to suffer in silence.
That sinking feeling in the pit of your stomach is familiar to those who have heard the words "you have cancer". Telling someone not to worry post treatment can be like telling them to not breathe. Listening is more productive than telling survivors not to worry.
Patient navigators are the vaunted “healthcare emissaries” for patients with breast cancer and can help navigate their journey a great deal. In this conversation from the Susan G. Komen Greater New York City “Empowering and Mobilizing Our Patient Navigation Workforce” virtual conference experts highlight the results of a survey of patient navigators.
WellBe, a new voice-enabled virtual assistant, can remind patients with cancer to take their medication and keep them on track from the comfort of their own home.
Although I was never a member of a sorority in the traditional sense, having breast cancer has put me into a sorority of women (and a few men) and created lifelong freidnships.
From the recent discovery of osteosarcoma in a dinosaur bone to NFL player Nate Solder opting out of the upcoming season for health concerns, here’s what’s making headlines in the cancer space this week.
On the Today Show, Scott Hamilton share's his cancer story and also gives a look at his book "Frtizy Finda A Hat", a children's book to help parents talk about cancer with their kids.
The FDA based its decision on data from a phase 2 trial which showed that MK-6482 induced clinical responses among patients with von Hippel-Lindau disease-associated kidney cancer.
Survey includes new data illustrating cancer patients’ mindsets during and after treatment.
